|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Prepaid Expenses | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| CURRENT LIABILITIES | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Related party note and interest payable | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
| Preferred stock, $.01 par value; authorized - 5,000,000 shares; issued - none | ||||||||||||||||||||
| Common stock, $.001 par value; authorized - 30,000,000 shares; issued and outstanding - 27,860,773 on September 30, 2025 and December 31, 2024 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| TOTAL STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
| TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
Loading...
